Under the deal, the firms will develop compatibility between Exablate Neuro and Siemens 1.5T and 3T clinical MRI systems such as Magnetom Aera and Skyra.
The partnership will also work to provide access to Exablate Neuro for installed base for installed base, in addition to new product installation customers.
Exablate Neuro is claimed to be the only CE mark and FDA-approved device for the non-invasive application of MR guided focused ultrasound to treat essential tremor and other conditions.
The device uses focused ultrasound waves to precisely target and accurately ablate tissue deep within the brain with no incisions.
Siemens MR imaging intends to offer patient-specific treatment planning and continuous temperature monitoring to assess treatment outcome in real-time during Exablate Neuro procedures.
According to InSightec, clinical research, development and regulatory approvals are ongoing for additional neurosurgical applications and markets.
InSightec CEO and board chairman Dr Maurice Ferré said: "Our agreement with Siemens Healthineers will allow us to significantly expand Exablate Neuro's market presence.
“Siemens has embraced our technology and together we will bring our therapy to significantly more patients and providers.”
Siemens Healthineers general manager and senior vice president Dr Christoph Zindel said: "This strategic partnership of two leading organizations is exciting and further underlines Siemens Healthineers' strategy of enabling better patient outcomes by broadening its diagnostic imaging portfolio into advanced therapies in the area of neurological and other disorders."
Image: Siemens and InSightec sign agreement to expand access to Exablate Neuro technology. Photo: courtesy of PRNewsFoto/Siemens Healthineers INSIGHTEC.
